ASCO recognizes Rep. Kevin Yoder with 2018 Congressional Leadership Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Society of Clinical Oncology has presented Rep. Kevin Yoder (R-KS) with the 2018 Congressional Leadership Award.

Each year, ASCO presents this award to a member of Congress who has continuously supported legislation that promotes an improved practice environment for the oncology community and improves the quality of care for cancer patients.

A member of the House Appropriations Committee and Co-Chair of the House Cancer Caucus, Rep. Yoder has worked tirelessly over the last three years to build support for sustainable funding increases for NIH and NCI.

He signed the Dear Colleague Letter to HHS in October 2017, which called for a correction to the Merit-based Incentive Payment System score adjustment to ensure the score is not applied to Part B Drug payments. The issue was resolved in February 2018.

Rep. Yoder continues to demonstrate his support for individuals with cancer through co-sponsorship of the Childhood Cancer Survivorship, Treatment, Access and Research Act of 2017 (H.R. 820), the Palliative Care, Hospice, Education, and Training Act (H.R. 1676), the Cancer Drug Parity Act (H.R. 1409), and the Restoring Patient’s Voice Act of 2017 (H.R. 2077).

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login